Abstract
Chronic Inflammatory Response Syndrome (CIRS) is a complex, multisystem illness driven by sustained innate immune activation following exposure to biotoxins such as mold, mycotoxins, Actinobacteria, and bacterial endotoxins in water-damaged buildings (WDB), as well as tick-borne and marine toxins. The CIRS Protocol is a sequential 12-step therapeutic framework designed to diagnose and resolve CIRS through a combination of environmental, pharmacologic, and biochemical interventions.
This paper outlines the clinical application of the protocol, beginning with Step 1—complete removal from biotoxin exposure—which requires advanced environmental assessment using qPCR, LAL assays, and other validated building clearance criteria. Step 2 involves removal of internal biotoxin reservoirs using bile acid sequestrants (cholestyramine/Welchol), following immune system priming with high-dose EPA/DHA fish oil. Subsequent steps address eradication of Multiple Antibiotic Resistant Coagulase Negative Staphylococci (MARCoNS,) correction of gliadin antibodies, and restoration of depleted androgens—particularly dehydroepiandrosterone (DHEA) often suppressed in CIRS due to Hypothalamic-Pituitary-Adrenal (HPA) axis dysregulation.
The protocol progresses to targeted correction of disrupted biomarkers including Antidiuretic Hormone (ADH)/osmolality, Matrix Metalloproteinase-9 (MMP-9), Vascular Endothelial Growth Factor (VEGF), Complement 3a (C3a), Complement 4a (C4a), and Transforming Growth Factor beta-1 (TGFβ-1), each linked to specific symptoms and tissue-level dysfunction. Evidence-based use of adjunctive agents such as fish oil, losartan, and vasoactive intestinal peptide (VIP) is discussed in depth, with rationale grounded in peer-reviewed clinical and mechanistic data.
When implemented in the prescribed sequence with precision, the CIRS Protocol results in measurable biomarker normalization and clinical resolution in most compliant patients, restoring neuroendocrine-immune homeostasis and function.
Despite evidence from peer-reviewed studies and human clinical trials, the CIRS Protocol remains outside of mainstream medical practice, while unvalidated treatments proliferate—leading to poor outcomes and resource exhaustion for patients. This review aims to provide a clear, detailed, and referenced guide to the CIRS Protocol to support provider education and address the growing need for competent care in biotoxin-related illness.